Skip to main content

Neoadjuvant Radiation Versus Upfront Surgery for Upper Rectal Cancer: A Systematic Review and Meta-Analysis of the Evidence

In brief

Neoadjuvant radiation cuts local recurrence by about a third in upper rectal cancer

A meta-analysis of 13 studies found that pre-operative radiation did not improve overall survival for upper rectal tumors but lowered the chance of the cancer returning locally by roughly 37 percent. The benefit appears limited to higher-risk cases, and the evidence is mixed because most data come from retrospective series.

Journal
The Journal of surgical research (Q1)
Published
10 August 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Ahmed A Eltahir, Oluseye K Oduyale, Vikram Pothuri, Michelle Doering, Catherine N Zivanov, Daniel Hong, et al.
PMID
42574955
DOI
10.1016/j.jss.2026.07.011

Why clinicians should know about it

  • Picked for Anatomy (top studies of the week, 16 August 2026): Neoadjuvant radiation vs surgery for upper rectal cancer
  • Picked for Oncology and Radiation Oncology (top studies of the week, 16 August 2026).
  • Picked for Surgery (top studies of the week, 16 August 2026): Neoadjuvant radiation reduces local recurrence in upper rectal cancer

Abstract

INTRODUCTION: Neoadjuvant radiation therapy (NRT) is a cornerstone in the treatment of lower and middle rectal cancers. However, the efficacy of NRT in upper rectal cancer remains debated due to conflicting recommendations and study outcomes. This study aims to re-evaluate the effects of NRT versus upfront surgery in upper rectal cancer through a comprehensive systematic review and meta-analysis of recent and relevant studies. METHODS: A systematic search was conducted in Ovid Medline, PubMed, Embase, Scopus, Cochrane Central, and Clinicaltrials.gov, filtering studies published from January 2002 onward to reflect contemporary treatment paradigms. We included randomized controlled trials and observational studies comparing outcomes between NRT and upfront surgery in upper rectal cancer. The primary outcomes were overall survival (OS) and local recurrence (LR). RESULTS: Thirteen studies met the inclusion criteria, comprising three randomized controlled trials and ten observational studies. Meta-analysis showed no statistically significant improvement in OS with NRT (risk ratio: 0.92, 95% confidence interval, 0.83-1.02), but a significant reduction in LR risk (risk ratio: 0.63, 95% confidence interval, 0.43-0.95). CONCLUSIONS: NRT does not significantly improve OS for upper rectal cancer patients but can reduce the risk of LR in select patients. These findings suggest a selective use of NRT in higher risk upper rectal cancers, especially considering potential adverse effects and the anatomical challenges in defining upper rectal cancer. The analysis was limited by the heterogeneity of study designs and the retrospective nature of most included studies.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.